FDA Clearance Tracker · K261929
Upper Arm Blood pressure monitor (BP7155D)
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Sep 10, 2026
Substantially Equivalent
Time to decision
93 days
Received Jun 9, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K261929
- Device name
- Upper Arm Blood pressure monitor (BP7155D)
- Applicant
- OMRON Healthcare, Inc.
- Applicant location
- Hoffman Estates, IL
- Received
- Jun 9, 2026
- Decided
- Sep 10, 2026
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device class
- Class II
- Regulation
- 21 CFR 870.1130
- Specialty
- Cardiology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code DXN. The earliest in FDA's data is K760930, decided Nov 9, 1976.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K261929
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for OMRON Healthcare, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
DEN230076 · Decided Oct 8, 2024 · 330 days after receipt
Device type: Oscillometric-Based, Over-The-Counter, Atrial Fibrillation Notification Feature (QXY) · Cardiology
K202228 · Decided Apr 1, 2021 · 237 days after receipt
Device type: System, Measurement, Blood-Pressure, Non-Invasive (DXN) · Cardiology
K183215 · Decided Sep 7, 2019 · 292 days after receipt
Device type: Stimulator, Nerve, Transcutaneous, Over-The-Counter (NUH) · Neurology & Neurosurgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.